inclusion criteria: * willing and able to provide written informed consent on their own prior to performing study procedures. in the u.k., subject assent or proxy consent as per local site procedures, may also be acceptable if both a clinician and second health professional attest that the subject understands the risks and potential benefits of the study and elects to proceed. outside the u.k., written informed consent may only be obtained from the subject or legally authorized representative. in the event the subject loses capacity during the study, the subject consents to continued participation, except where this is not clinically indicated. * willing and able to comply with study-related procedures/assessments * age 18 to 80 years old * hospitalized (or documentation of a plan to admit to the hospital if the subject is in an emergency department) and requiring supplemental oxygen to maintain saturation \> 90% * a diagnosis of symptomatic covid-19 defined as a positive test for sars-cov-2 rna detected by rt-pcr on a sample from the upper respiratory tract (e.g., nasopharyngeal, nasal, or oropharyngeal swab) collected \< 72 hours prior to randomization * onset of covid-19 -related symptoms \> 2 days and \</= 10 days prior to hospital admission

inclusion criteria: * willing and able to provide written informed consent on their own prior to performing study procedures. in the u.k., subject assent or proxy consent as per local site procedures, may also be acceptable if both a clinician and second health professional attest that the subject understands the risks and potential benefits of the study and elects to proceed. outside the u.k., written informed consent may only be obtained from the subject or legally authorized representative. in the event the subject loses capacity during the study, the subject consents to continued participation, except where this is not clinically indicated. * willing and able to comply with study-related procedures/assessments * age 18 to 80 years old * hospitalized (or documentation of a plan to admit to the hospital if the subject is in an emergency department) and requiring supplemental oxygen to maintain saturation \> 90% * a diagnosis of symptomatic covid-19 defined as a positive test for sars-cov-2 rna detected by rt-pcr on a sample from the upper respiratory tract (e.g., nasopharyngeal, nasal, or oropharyngeal swab) collected \< 72 hours prior to randomization * onset of covid-19 -related symptoms \> 2 days and \</= 10 days prior to hospital admission

inclusion criteria: - willing and able to provide written informed consent on their own prior to performing study procedures. in the u.k., subject assent or proxy consent as per local site procedures, may also be acceptable if both a clinician and second health professional attest that the subject understands the risks and potential benefits of the study and elects to proceed. outside the u.k., written informed consent may only be obtained from the subject or legally authorized representative. in the event the subject loses capacity during the study, the subject consents to continued participation, except where this is not clinically indicated. - willing and able to comply with study-related procedures/assessments - age 18 to 80 years old - hospitalized (or documentation of a plan to admit to the hospital if the subject is in an emergency department) and requiring supplemental oxygen to maintain saturation > 90% - a diagnosis of symptomatic covid-19 defined as a positive test for sars-cov-2 rna detected by rt-pcr on a sample from the upper respiratory tract (e.g., nasopharyngeal, nasal, or oropharyngeal swab) collected < 72 hours prior to randomization - onset of covid-19 -related symptoms > 2 days and </= 10 days prior to hospital admission

inclusion criteria: - willing and able to provide written informed consent on their own prior to performing study procedures. in the u.k., subject assent or proxy consent as per local site procedures, may also be acceptable if both a clinician and second health professional attest that the subject understands the risks and potential benefits of the study and elects to proceed. outside the u.k., written informed consent may only be obtained from the subject or legally authorized representative. in the event the subject loses capacity during the study, the subject consents to continued participation, except where this is not clinically indicated. - willing and able to comply with study-related procedures/assessments - age 18 to 80 years old - hospitalized (or documentation of a plan to admit to the hospital if the subject is in an emergency department) and requiring supplemental oxygen to maintain saturation > 90% - a diagnosis of symptomatic covid-19 defined as a positive test for sars-cov-2 rna detected by rt-pcr on a sample from the upper respiratory tract (e.g., nasopharyngeal, nasal, or oropharyngeal swab) collected < 72 hours prior to randomization - onset of covid-19 -related symptoms > 2 days and </= 10 days prior to hospital admission